Itrasys SB 65mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent effective against a variety of fungal infections. It functions by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to fungal cell death. Itrasys SB is indicated for the treatment of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. The 65mg dosage form allows for flexible dosing regimens tailored to the severity and type of infection. Itraconazole exhibits good oral bioavailability, with enhanced absorption when taken with food, and extensive tissue penetration, making it suitable for infections involving skin, nails, and internal organs. It is metabolized primarily by the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions with agents metabolized through the same pathway. Common adverse effects include gastrointestinal disturbances, headache, and elevated liver enzymes. Itrasys SB should be used under medical supervision, with periodic monitoring of liver function and therapeutic response. Contraindications include hypersensitivity to itraconazole and concurrent use with certain drugs such as cisapride and terfenadine. This medication provides an effective option for managing complex fungal infections requiring systemic antifungal therapy.